Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 55/100

Failure Rate

22.2%

6 terminated/withdrawn out of 27 trials

Success Rate

76.9%

-9.6% vs industry average

Late-Stage Pipeline

63%

17 trials in Phase 3/4

Results Transparency

20%

4 of 20 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 3
11(45.8%)
Phase 4
6(25.0%)
Phase 2
5(20.8%)
Phase 1
2(8.3%)
24Total
Phase 3(11)
Phase 4(6)
Phase 2(5)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (27)

Showing 20 of 27 trials
NCT00182455Phase 4Terminated

Efficacy of Adding Topiramate to Current Treatment in Treatment-Resistant Generalized Social Phobia (GSP)

Role: collaborator

NCT00182520Phase 4Completed

Efficacy of Adding Topiramate to Current Treatment in Refractory Obsessive Compulsive Disorder (OCD)

Role: collaborator

NCT00269971Phase 3Withdrawn

A Study to Determine an Effective Dose of Epoetin Alfa to Decrease the Number of Units of Blood Required to be Transfused During Hip Replacement Surgery.

Role: lead

NCT00799539Unknown

A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

Role: lead

NCT01977300Phase 3Completed

Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode

Role: collaborator

NCT01424930Phase 2Completed

A Study to Determine the Short-Term Safety of Continuous Dosing of Abiraterone Acetate and Prednisone in Modified Fasting and Fed States to Patients With Metastatic Castration-Resistant Prostate Cancer

Role: lead

NCT00246259Phase 4Completed

A Trial Comparing Risperidone Long-Acting Injection With Oral Antipsychotic in the Treatment of Early Psychosis

Role: lead

NCT00256997Phase 4Terminated

A Study of Risperidone Long-Acting Injection Versus Oral Antipsychotics in Schizophrenia Participants With a History of Being Poorly Compliant With Taking Their Medication

Role: lead

NCT00718640Phase 2Terminated

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

Role: lead

NCT01484301Completed

Impact of Tolerability Issues on Chronic Pain

Role: lead

NCT01118702Phase 1Completed

A Study to Explore Plasma Levels of CONCERTA, Ritalin-SR and Novo-Methylphenidate ER-C in Healthy Volunteers

Role: lead

NCT00378287Phase 1Completed

A Study to Monitor Intragastric pH in Patients Taking Rabeprazole vs. Patients Taking Pantoprazole

Role: lead

NCT00246207Phase 3Completed

CONCERTA (OROS Methylphenidate Hydrochloride) for the Treatment of Attention Deficit Hyperactivity Disorder in Adults

Role: lead

NCT00561743Phase 2Completed

A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

Role: lead

NCT00553449Phase 3Completed

Open Label Study Evaluating Different Dosing Regimens of Rabeprazole in Gastro-esophageal Reflux Disease (GERD) Patients With Night-time Heartburn Symptoms.

Role: lead

NCT00269958Phase 2Completed

A Study to Evaluate the Safety and Efficacy of Epoetin Alfa Versus Placebo to Reduce the Need for Blood Transfusions and Reduce the Occurrence of Severe Anemia During the Time Period Surrounding Total Hip Replacement Surgery

Role: lead

NCT00246233Phase 3Completed

CONCERTA® (Methylphenidate Hydrochloride) as add-on Therapy in the Treatment of Adult Major Depressive Disorder.

Role: lead

NCT00304681Phase 3Completed

An Effectiveness and Safety Study of CONCERTA* vs. Immediate Release Methylphenidate (IR MPH) in Attention Deficit Hyperactivity Disorder Children

Role: lead

NCT00261469Phase 2Completed

An Open-label Study to Evaluate Topiramate Therapy in Migraine Patients, and Its Effects on Subject Responsiveness to Migraine Treatment With Triptans

Role: lead

NCT00246246Phase 3Completed

A Randomized, Open-label Trial of Long-acting Injectable Risperidone Versus Oral Antipsychotic Medication in Patients With Bipolar Disorder

Role: lead